BST Position Update – July 24, 2015
. . . . Progenics Pharmaceuticals (NASDAQ: $PGNX) – Hold
There’s a lot to like about Progenics stock price action lately. The stock made a new high of $9.27. That’s a 69% gain from where we bought it. At a current price of $8.64, PGN is up 58%.
What’s more, earnings estimates for the company are moving higher as analysts’ eye increased sales from Relistor. And a Phase 3 clinical trial is in the works for their 1404 program to detect prostate cancer.
It’s obviously great news to see our shares up 58% in about two months.
Continue holding PGNX for bigger gains ahead.
. . . . POZEN (NASDAQ: $POZN) – Hold
POZN had an amazing run from June 1st to June 22nd. During that time, the stock nearly double in price!
Right now POZN is trading for $11.45. That’s up 49% from where we recommended it a few months back.
Needless to say, it’s great to see some of our recent recommendations taking off to the upside… and doing it right out of the gate.
. . . . Xencor (NASDAQ: $XNCR) – Hold
XNCR is the top performing stock in our portfolio right now. At $23.91, it’s up 179%. We already sold half our position when the stock doubled. Now we’re playing with the house’s money.
We knew XNCR received a $175 million cash infusion from a bigger biotech to fund their research into XmAb technologies. And not too long ago, the company revealed they were starting new clinical trials for products based on this technology.
In short, Xencor is hot on the trail of a major breakthrough on the way we treat many different forms of cancer. Continue holding.
. . . . Synergy Pharmaceuticals (NASDAQ: $SGYP) – Hold
SGYP had a breakout moment in mid-June. On June 16th, the stock finished the day at $4.64. Just two days later, on June 18th, the stock had more than doubled to $9.44.
Right now SGYP is up 89% from where I recommended buying it.
The company is expecting more Phase 3 trials soon. Continue holding for more upside.
Action To Take
- Move POZN to Hold.
Category: BST Update
